Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
SUPN's Cash-to-Debt is ranked higher than
67% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. SUPN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SUPN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 3.48 Max: No Debt
Current: No Debt
Equity-to-Asset 0.65
SUPN's Equity-to-Asset is ranked higher than
54% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SUPN: 0.65 )
Ranked among companies with meaningful Equity-to-Asset only.
SUPN' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.25  Med: 0.47 Max: 0.68
Current: 0.65
-2.25
0.68
Debt-to-EBITDA 0.02
SUPN's Debt-to-EBITDA is ranked higher than
98% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. SUPN: 0.02 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SUPN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7  Med: -0.48 Max: 5.48
Current: 0.02
-7
5.48
Interest Coverage 34.36
SUPN's Interest Coverage is ranked lower than
62% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. SUPN: 34.36 )
Ranked among companies with meaningful Interest Coverage only.
SUPN' s Interest Coverage Range Over the Past 10 Years
Min: 1  Med: 4.37 Max: 34.36
Current: 34.36
1
34.36
Piotroski F-Score: 5
Altman Z-Score: 10.29
Beneish M-Score: -2.62
WACC vs ROIC
14.27%
48.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 29.51
SUPN's Operating Margin % is ranked higher than
95% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. SUPN: 29.51 )
Ranked among companies with meaningful Operating Margin % only.
SUPN' s Operating Margin % Range Over the Past 10 Years
Min: -37851.89  Med: -290.93 Max: 29.51
Current: 29.51
-37851.89
29.51
Net Margin % 20.98
SUPN's Net Margin % is ranked higher than
97% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. SUPN: 20.98 )
Ranked among companies with meaningful Net Margin % only.
SUPN' s Net Margin % Range Over the Past 10 Years
Min: -36285.85  Med: -11.79 Max: 6701.74
Current: 20.98
-36285.85
6701.74
ROE % 27.53
SUPN's ROE % is ranked higher than
98% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. SUPN: 27.53 )
Ranked among companies with meaningful ROE % only.
SUPN' s ROE % Range Over the Past 10 Years
Min: -202.72  Med: -29.46 Max: 65.21
Current: 27.53
-202.72
65.21
ROA % 17.57
SUPN's ROA % is ranked higher than
98% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. SUPN: 17.57 )
Ranked among companies with meaningful ROA % only.
SUPN' s ROA % Range Over the Past 10 Years
Min: -90.03  Med: -8.82 Max: 106.84
Current: 17.57
-90.03
106.84
ROC (Joel Greenblatt) % 1874.82
SUPN's ROC (Joel Greenblatt) % is ranked higher than
100% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. SUPN: 1874.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SUPN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4247.75  Med: -1300.86 Max: 1874.82
Current: 1874.82
-4247.75
1874.82
3-Year Revenue Growth Rate 122.60
SUPN's 3-Year Revenue Growth Rate is ranked higher than
99% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. SUPN: 122.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SUPN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 70.8 Max: 223.7
Current: 122.6
0
223.7
GuruFocus has detected 2 Warning Signs with Supernus Pharmaceuticals Inc SUPN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SUPN's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

SUPN Guru Trades in Q4 2016

Steven Cohen 1,900 sh (New)
Paul Tudor Jones 27,577 sh (+86.33%)
Robert Bruce 164,581 sh (unchged)
» More
Q1 2017

SUPN Guru Trades in Q1 2017

Joel Greenblatt 102,001 sh (New)
Chuck Royce 130,000 sh (New)
Jeremy Grantham 8,200 sh (New)
Steven Cohen Sold Out
Robert Bruce 64,581 sh (-60.76%)
Paul Tudor Jones 10,548 sh (-61.75%)
» More
Q2 2017

SUPN Guru Trades in Q2 2017

Ron Baron 44,602 sh (New)
Chuck Royce 159,000 sh (+22.31%)
Jeremy Grantham 8,200 sh (unchged)
Paul Tudor Jones Sold Out
Robert Bruce 34,581 sh (-46.45%)
Joel Greenblatt 24,381 sh (-76.10%)
» More
Q3 2017

SUPN Guru Trades in Q3 2017

Joel Greenblatt 168,536 sh (+591.26%)
Robert Bruce 178,058 sh (+414.90%)
Ron Baron 89,621 sh (+100.93%)
Jeremy Grantham 8,200 sh (unchged)
Chuck Royce 159,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Robert Bruce 2017-09-30 Add 414.90%1.41%$36.75 - $49.65 $ 38.00-12%178,058
Joel Greenblatt 2017-09-30 Add 591.26%0.09%$36.75 - $49.65 $ 38.00-12%168,536
Ron Baron 2017-09-30 Add 100.93%0.01%$36.75 - $49.65 $ 38.00-12%89,621
Ron Baron 2017-06-30 New Buy0.01%$30.15 - $44.15 $ 38.007%44,602
Robert Bruce 2017-06-30 Reduce -46.45%0.25%$30.15 - $44.15 $ 38.007%34,581
Joel Greenblatt 2017-06-30 Reduce -76.10%0.03%$30.15 - $44.15 $ 38.007%24,381
Joel Greenblatt 2017-03-31 New Buy0.04%$23.45 - $31.3 $ 38.0042%102,001
Robert Bruce 2017-03-31 Reduce -60.76%0.75%$23.45 - $31.3 $ 38.0042%64,581
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:XLJU:KRKG, TSE:4521, NAS:MDCO, SHSE:600267, TSE:4555, SZSE:300199, SHSE:603567, XKRX:041960, NAS:HZNP, NAS:IRWD, SZSE:002390, SZSE:300110, SHSE:600329, TSX:WEED, SZSE:000078, SHSE:600380, SHSE:600216, SHSE:600277, SHSE:603707, BOM:532296 » details
Traded in other countries:S49.Germany,
Headquarter Location:USA
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Top Ranked Articles about Supernus Pharmaceuticals Inc

Supernus to Present at Three November Healthcare Conferences
Supernus to Host Third Quarter 2017 Earnings Conference Call
Supernus Provides Update on SPN-810 Phase III Clinical Trials
Supernus Defeats Second Generic Challenger to Oxtellar XR®
Supernus to Host Second Quarter 2017 Earnings Conference Call
Supernus Announces that its Partner Shire Receives FDA Approval for Mydayis™ for ADHD
Supernus to Present at Jefferies Healthcare Conference
Supernus to Host First Quarter 2017 Earnings Conference Call
Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents
Supernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation
ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a binding term sheet with Actavis Laboratories, FL, Inc. et al. (collectively, “Actavis”, now a subsidiary of Teva Pharmaceuticals Industries, Ltd.) involving the ongoing patent litigation regarding Actavis’ Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Supernus’ Trokendi XR® (extended-release topiramate) capsules.  The binding term sheet permits Actavis to begin selling a generic version of Trokendi XR® on January 1, 2023, or earlier under certain circumstances.  The binding term sheet will be submitted to the applicable governmental agencies.
Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR®.  Patent protection for Trokendi XR® expires no earlier than 2027.Supernus is represented by attorneys from Haug Partners LLP and its corporate counsel, Saul Ewing LLP.About Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.Forward Looking StatementsThis press release contains forward-looking statements regarding the Company’s ability to defend and enforce its intellectual property rights covering Trokendi XR®. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, the ability of Supernus to finance potential litigation and to prevail in any such proceeding to successfully defend its intellectual property rights. For a further description of these and other risks facing the Company, please see the risk factors described in the Company’s 2015 Annual Report Form 10-K/A that was filed with the United States Securities and Exchange Commission on January 20, 2017 under the caption “Risk Factors”.  Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as may be required by law.
Contact:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
301-838-2591

Or

Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 35.19
SUPN's PE Ratio is ranked higher than
65% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. SUPN: 35.19 )
Ranked among companies with meaningful PE Ratio only.
SUPN' s PE Ratio Range Over the Past 10 Years
Min: 0.13  Med: 38.19 Max: 235.67
Current: 35.19
0.13
235.67
Forward PE Ratio 22.08
SUPN's Forward PE Ratio is ranked lower than
51% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. SUPN: 22.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 35.19
SUPN's PE Ratio without NRI is ranked higher than
66% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. SUPN: 35.19 )
Ranked among companies with meaningful PE Ratio without NRI only.
SUPN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.37  Med: 43.77 Max: 235.67
Current: 35.19
11.37
235.67
Price-to-Owner-Earnings 21.22
SUPN's Price-to-Owner-Earnings is ranked higher than
77% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. SUPN: 21.22 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SUPN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.56  Med: 24.02 Max: 172.44
Current: 21.22
9.56
172.44
PB Ratio 7.74
SUPN's PB Ratio is ranked lower than
88% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. SUPN: 7.74 )
Ranked among companies with meaningful PB Ratio only.
SUPN' s PB Ratio Range Over the Past 10 Years
Min: 3.23  Med: 7.59 Max: 18.53
Current: 7.74
3.23
18.53
PS Ratio 7.29
SUPN's PS Ratio is ranked lower than
78% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. SUPN: 7.29 )
Ranked among companies with meaningful PS Ratio only.
SUPN' s PS Ratio Range Over the Past 10 Years
Min: 3.77  Med: 7.34 Max: 157
Current: 7.29
3.77
157
Price-to-Free-Cash-Flow 19.82
SUPN's Price-to-Free-Cash-Flow is ranked higher than
54% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. SUPN: 19.82 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SUPN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.51  Med: 23.64 Max: 82.21
Current: 19.82
15.51
82.21
Price-to-Operating-Cash-Flow 19.52
SUPN's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. SUPN: 19.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SUPN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.96  Med: 23.06 Max: 76.29
Current: 19.52
14.96
76.29
EV-to-EBIT 21.96
SUPN's EV-to-EBIT is ranked lower than
62% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. SUPN: 21.96 )
Ranked among companies with meaningful EV-to-EBIT only.
SUPN' s EV-to-EBIT Range Over the Past 10 Years
Min: -72.8  Med: -0.95 Max: 96
Current: 21.96
-72.8
96
EV-to-EBITDA 20.23
SUPN's EV-to-EBITDA is ranked lower than
68% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. SUPN: 20.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
SUPN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -90.8  Med: -1 Max: 88.7
Current: 20.23
-90.8
88.7
EV-to-Revenue 6.64
SUPN's EV-to-Revenue is ranked lower than
75% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. SUPN: 6.64 )
Ranked among companies with meaningful EV-to-Revenue only.
SUPN' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.3  Med: 7.3 Max: 652.7
Current: 6.64
3.3
652.7
Current Ratio 1.82
SUPN's Current Ratio is ranked lower than
61% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. SUPN: 1.82 )
Ranked among companies with meaningful Current Ratio only.
SUPN' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 2.83 Max: 8.39
Current: 1.82
1.51
8.39
Quick Ratio 1.68
SUPN's Quick Ratio is ranked lower than
53% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. SUPN: 1.68 )
Ranked among companies with meaningful Quick Ratio only.
SUPN' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.63 Max: 8.39
Current: 1.68
1.49
8.39
Days Inventory 418.28
SUPN's Days Inventory is ranked lower than
97% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. SUPN: 418.28 )
Ranked among companies with meaningful Days Inventory only.
SUPN' s Days Inventory Range Over the Past 10 Years
Min: 418.28  Med: 608.33 Max: 1372.72
Current: 418.28
418.28
1372.72
Days Sales Outstanding 74.23
SUPN's Days Sales Outstanding is ranked higher than
50% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. SUPN: 74.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
SUPN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.71  Med: 69.26 Max: 16387.12
Current: 74.23
2.71
16387.12
Days Payable 154.09
SUPN's Days Payable is ranked higher than
88% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. SUPN: 154.09 )
Ranked among companies with meaningful Days Payable only.
SUPN' s Days Payable Range Over the Past 10 Years
Min: 118.1  Med: 216.12 Max: 1038.8
Current: 154.09
118.1
1038.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.70
SUPN's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. SUPN: -7.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SUPN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -199.2  Med: -12.35 Max: 0
Current: -7.7
-199.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 33.93
SUPN's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. SUPN: 33.93 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SUPN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.98  Med: 27.23 Max: 122.18
Current: 33.93
3.98
122.18
Price-to-Tangible-Book 9.08
SUPN's Price-to-Tangible-Book is ranked lower than
84% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. SUPN: 9.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SUPN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.86  Med: 7.91 Max: 19.49
Current: 9.08
3.86
19.49
Price-to-Intrinsic-Value-Projected-FCF 7.16
SUPN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
88% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. SUPN: 7.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SUPN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 7.16  Med: 24.34 Max: 37.71
Current: 7.16
7.16
37.71
Price-to-Median-PS-Value 1.00
SUPN's Price-to-Median-PS-Value is ranked lower than
58% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. SUPN: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SUPN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 1 Max: 16.08
Current: 1
0.52
16.08
Price-to-Graham-Number 3.77
SUPN's Price-to-Graham-Number is ranked lower than
72% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.97 vs. SUPN: 3.77 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SUPN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.17  Med: 3.9 Max: 8.71
Current: 3.77
2.17
8.71
Earnings Yield (Greenblatt) % 4.55
SUPN's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. SUPN: 4.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SUPN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -105.6  Med: -1.4 Max: 5.5
Current: 4.55
-105.6
5.5

More Statistics

Revenue (TTM) (Mil) $276.18
EPS (TTM) $ 1.08
Beta1.93
Short Percentage of Float9.21%
52-Week Range $20.55 - 50.05
Shares Outstanding (Mil)51.26

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) 1.09 1.72
EPS without NRI ($) 1.09 1.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}